Evidence Requirements by Different Stakeholders for Health Care Decisions in Asia-Pacific

PROGRAM AND SCHEDULE OF EVENTS

CO-ORGANIZED BY:
ISPOR Asia Consortium
Taiwan Center for Drug Evaluation
Taiwan Society for Pharmacoconomics and Outcomes Research

www.ispor.org
SUNDAY, 2 SEPTEMBER

8:00AM-12:00PM MORNING SHORT COURSES Short Course registration required
- Introduction toPharmacoeconomics Room 201D (2nd Floor)
- Introduction to Modeling Room 201F (2nd Floor)
- Introduction to Retrospective Database Design and Analysis Room 201A (2nd Floor)
- Introduction to Health Technology Assessment Room 201BC (2nd Floor)
- Introduction to Patient-Reported Outcomes Room 103 (1st Floor)
- Meta-Analysis and Systematic Literature Review Room 201E (2nd Floor)

1:00PM-5:00PM AFTERNOON SHORT COURSES Short Course registration required
- Financial Impact / Cost of Illness Room 103 (1st Floor)
- Statistical Considerations in Health Economic Evaluations Room 201D (2nd Floor)
- Transferability of Cost-Effectiveness Data Between Countries Room 201A (2nd Floor)
- Applied Modeling Room 201E (2nd Floor)
- Pharmaceutical/Biotech Pricing & Reimbursement Methodologies Room 201BC (2nd Floor)
- Network Meta-Analysis and Indirect Treatment Comparisons Room 201F (2nd Floor)

5:15PM-6:15PM EDUCATIONAL SYMPOSIUM Room 102 (1st Floor)
Conducting Real-World Non-Interventional Studies in Multiple Countries: Why, When and How? Sponsored by Novartis

6:30PM-7:30PM EDUCATIONAL SYMPOSIUM Room 102 (1st Floor)
Health Economics and Outcomes Research in Personalized Medicine Sponsored by Pfizer

7:45PM-8:45PM EDUCATIONAL SYMPOSIUM Room 102 (1st Floor)

9:00PM-11:00PM WELCOME RECEPTION Jade (2nd Floor)
All attendees welcome!

MONDAY, 3 SEPTEMBER

8:30AM-8:30PM RESEARCH POSTERS – I Room 201 (2nd Floor)

8:30AM-9:00AM WELCOME Room 101 (1st Floor)
Chinese/English translation
Welcome from Program Committee Co-Chairs
Welcome from ISPOR Asia Consortium Executive Committee Chair
Welcome from ISPOR President
Welcome from Taipei Mayor

9:00AM-9:15AM OPENING SPEECH Room 101 (1st Floor)
Chinese/English translation
The Future of Taiwan Health Care System and Policies

9:15AM-10:45AM FIRST PLENARY SESSION Room 101 (1st Floor)
Chinese/English translation
Health Technology Assessment in the Significantly Evolving Health Care Systems in Asia

10:45AM-11:00AM BREAK, EXHIBITS & RESEARCH POSTERS – I

11:00AM-12:00PM ISSUE PANELS & WORKSHOPS – I
Chinese/English translation
- IP1: How to Harmonize HTA and Value for Innovation? Room 101 (1st Floor)
- W1: Using Individual Simulation to Forecast Disease Epidemiology and Burden of Illness North Lounge (3rd Floor)
- W2: Integration of Survival With Quality of Life for Outcomes Research: Sharing of a Free Software Room 105 (1st Floor)

8:30AM-9:00AM WELCOME Room 101 (1st Floor)
Chinese/English translation
All attendees welcome!

9:00AM-10:00AM MORNING SESSION Room 101 (1st Floor)

10:30AM-11:30AM AFTERNOON SESSION Room 101 (1st Floor)

11:45AM-12:45PM BREAK, EXHIBITS & RESEARCH POSTERS – II

12:30PM-1:30PM EDUCATIONAL SYMPOSIUM Room 101 (1st Floor)
Chinese/English translation
Clinical Endpoints: Final Versus Surrogate Endpoint - Implications and Relevance From a Payer, Physician and Patient Perspective Sponsored by Eli Lilly and Company

1:45PM-2:45PM EDUCATIONAL SYMPOSIUM Room 101 (1st Floor)
Real-World Evidence: Meeting the Challenge of Stakeholder Needs for Demonstrating Value in Asia Sponsored by IMS Health

3:00PM-4:30PM WELCOME & SECOND PLENARY SESSION Room 101 (1st Floor)
Chinese/English translation
Involving Patients & Health Care Practitioners in Health Care Decisions: Learning From Each Other

4:30PM-4:45PM BREAK, EXHIBITS & RESEARCH POSTERS – II

4:45PM-5:45PM RESEARCH PODIUMS – II

5:15PM-6:15PM COST-EFFECTIVENESS STUDIES Room 103 (1st Floor)
CE1: The Cost-Effectiveness Analysis of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) in Taiwan
CE2: Cost-Effectiveness of the Real-World Use of Nucleic Acid Test Screening to Donated Blood for Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus: Experience From Taiwan, A Country With a High Prevalence of Hepatitis B and C Infections
CE3: Hyperbaric Oxygen Therapy for the Treatment Non-Neurological Soft Tissue Radiation Injuries: A Cost-Effectiveness Analysis
CE4: Cost-Effectiveness of Dabigatran Compared to Genotype-Guided Warfarin Dosing for Stroke Prophylaxis in Atrial Fibrillation Patients

5:45PM-6:45PM DIABETES OUTCOMES STUDIES Room 105 (1st Floor)
DB1: Epidemiology, Treatment and Economic Burden of Type 2 Diabetes Mellitus With Nephropathy Complications in China
DB2: Vitamin D Deficiency and Diabetes: Perceptions of Pharmacists and Physicians
DB3: Indirect Treatment Comparison (ITC) or Cost Effectiveness Analysis (CEA): A Study
DB4: Screening for Diabetic Retinopathy in Hong Kong: Is Inverse Care Law Operating?

7:00PM-8:00PM HEALTH CARE USE AND POLICY STUDIES Room 101 (1st Floor)
HC1: Price Premium for Innovation? Cost Calculation Method in Japan vs. Cost Utility Analysis in South Korea
HC2: A Review of Economic Evaluations of New Drugs Declared By the Similar Drug Comparison Method in Japan: Did Cost-Effectiveness Results Justify Premiums?
HC3: The Process of Updating the Items of National Health Insurance Benefits Schedule in Taiwan: Is It Fair and Legitimate?
HC4: Tapping Into the Asian Pharmaceutical Market: Global Firms Go Local?

8:00PM-9:00PM RESEARCH ON METHODS STUDIES South Lounge (3rd Floor)
ME1: Comparison of the Measurement Properties Between the 5-Level EuroQol Group’s 5-Dimension (EQ-5D-5L) Questionnaire and the Functional Assessment of Cancer Therapy – Breast (FACT-B) in Asian Breast Cancer Patients
ME2: Validation of the Kidney Disease and Quality of Life Questionnaire (KDQOL-36) in Haemodialysis Patients in Singapore
Tuesday, 4 September

8:30AM-5:00PM RESEARCH POSTERS – II Room 201 (2nd Floor)

8:30AM-10:00AM WELCOME & THIRD PLENARY SESSION Room 101 (1st Floor)

Chinese/English translation
Challenges of Adopting New Innovative Technologies in Health Care Coverage Decision-Making in Asia
CONFERECE OBJECTIVES
Participants will be able to:
• Learn new pharmacoeconomic methodologies and outcomes research techniques;
• Improve the quality of their decision making by better utilization of pharmacoeconomic studies; and
• Learn the latest about measuring quality of life and selecting appropriate survey instruments.

CONFERENCE LANGUAGES/TRANSLATION
The official Conference language is English. Plenary sessions will be presented in English and Chinese with Chinese/English and English/Chinese translation provided. Translated sessions are indicated with a headset symbol in the Program & Schedule of Events. Translation supported by Eli Lilly.

REGISTRATION MATERAILs
The following materials are included in your registration envelope:
• Short Course ticket for each Short Course for which you registered (you MUST bring your ticket to the Short Course room to collect materials);
• Attendee list which includes attendee name, organization, and country, based on the data collected at the time of registration; and
• Other promotional information.

PLEASE NOTE: Registration bags are available for pick-up near registration.

CONFERENCE REGISTRATION/SESSIONS
Separate registration is required for all Short Courses (Sunday, 2 September). Please see ISPOR Registration for details. A schedule of ISPOR Group meetings, which are by invitation only, is provided on page 28.

Conference registration is inclusive of symposia and the Welcome Reception on Sunday, 2 September and all sessions Monday and Tuesday. We encourage use of the new ISPOR Personal Scheduler at http://ispor.confex.com/ispor/asias7/schedule/index.cgi (or scan this QR code) which enables you to select the sessions you wish to attend and create a personal daily Conference itinerary.

ISPOR SOCIAL MEDIA
Follow ISPOR through:

ISPOR LinkedIn Discussion Group:
http://www.linkedin.com/groups?gid=4158822&trk=hb_side_g
ISPOR LinkedIn Company Page: http://www.linkedin.com/company/international-society-for-pharmacoeconomics-and-outcomes-research

Twitter: Follow @ISPORorg
Be part of the live discussion! Tweet your comments during the Conference using #ISPORTaipei

RESEARCH PODIUM & POSTER ABSTRACTS
Abstracts for all research podium and poster presentations given at the ISPOR 5th Asia-Pacific Conference will be published in Value in Health Volume 15, Issue 7. Value in Health Volume 15, Issue 7 will be available to ISPOR members and 5th Asia-Pacific Conference registrants on-line at http://www.ispor.org/valueinhealth_index.asp in October 2012. Research podium, poster, and health care decision-maker abstracts are also included in this Program & Schedule of Events. See page 31-54 for a listing of Poster Presentations (Research and Case Studies) and the Schedule of Events section for Research Podium Presentations. Page numbers to the left of the presentation code refer to the abstract location in this Program & Schedule of Events.

FINANCIAL DISCLOSURE INFORMATION
Research podium and poster presentation financial disclosure information is available online in October 2012 at: http://www.ispor.org/valueinhealth_index.asp and in Value in Health Volume 15, Issue 7. Faculty and staff involved in the planning or presentation of this meeting are required to disclose all real or apparent commercial financial affiliations related to conference content. This information can also be requested at the ISPOR Registration Desk.

HANDOUTS/PRESENTATION SLIDES/POSTERS
HANOUTS
• Plenary Sessions
Handouts for the plenary session are available in the session room at the time of the presentations.
• Research Presentations, Workshops & Issue Panels
Handouts for research (podiums and posters), workshops, and issue panels are the sole responsibility of the presenting author(s). ISPOR requires all contributed presenters to provide at least 200 copies of their handouts.
• Sponsored Symposia
Handouts for symposia are the sole responsibility of the host organization. ISPOR suggests all symposium hosts provide at least 200 copies of their handout.
• All Remaining & Additional Handouts
All remaining or additional handouts will be made available at the handout table near ISPOR Registration.

PRESENTATION SLIDES/POSTERS
Conference plenary session, issue panel, workshop, and symposia slides as PDFs will be available at www.ispor.org after the Conference, subject to speaker approval.

Podium & poster presentation abstracts and released slide or poster PDFs are available at the ISPOR Outcomes Research Digest (a searchable database of over 20,000 research papers presented at ISPOR meetings) at http://www.ispor.org/research_study_digest/index.asp or scan this QR code.

ABSTRACT SUBMISSION HISTORICAL INFORMATION
During the ISPOR 5th Asia-Pacific Meeting, 408 posters, 40 research podiums, 15 workshops and 5 issue panels will be presented.

<table>
<thead>
<tr>
<th>Year</th>
<th>Research Workshop</th>
<th>Issue Panel</th>
<th>Case Studies</th>
<th>Total</th>
<th>Not Accepted (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>92</td>
<td>12</td>
<td>-</td>
<td>104</td>
<td>7.6%</td>
</tr>
<tr>
<td>2006</td>
<td>211</td>
<td>23</td>
<td>-</td>
<td>234</td>
<td>8.1%</td>
</tr>
<tr>
<td>2008</td>
<td>280</td>
<td>14</td>
<td>4</td>
<td>298</td>
<td>12.7%</td>
</tr>
<tr>
<td>2010</td>
<td>281</td>
<td>17</td>
<td>9</td>
<td>6</td>
<td>413</td>
</tr>
<tr>
<td>2012</td>
<td>478</td>
<td>27</td>
<td>11</td>
<td>4</td>
<td>520</td>
</tr>
</tbody>
</table>

SPEAKER INFORMATION
All speakers are requested to arrive at their presentation room 15 minutes prior to the session start time with their presentation on a USB/Flash Drive and required handouts (for podium, workshop, and issue panel presentations). ISPOR staff will assist the presenter with loading their presentation. Please note that all presentations submitted to ISPOR by the specified advance deadline will be pre-loaded onto the computer in the session room.

A self service business area is located on the first floor near Room 105. Cash cards, to use for making photocopies, can be purchased at the TICC desk.
***ISPOR RESEARCH PRESENTATION AWARDS***

Awards are given for the Best Research Podium Presentations (up to 6) and for the Best Research Poster Presentations (up to 6).

All research podium presentations are considered for an award. Research poster presentations in the top 10%, based on abstract review score, are considered for a poster presentation award. These are identified with a rosette and will be judged during the Conference.

**ISPOR 5th Asia-Pacific Conference Research Presentation Awards will be presented on Tuesday, 4 September at 5:15PM.**

***EXHIBITS***

Exhibits will be on view in **Room 201 (2nd Floor).**

- Monday, 3 September: 8:30AM-8:30PM
- Tuesday, 4 September: 8:30AM-5:00PM

***eJOBS EMPLOYMENT CENTER New!***

An interview room is available during the Conference as a feature of the new ISPOR eJOBS Employment Center. Candidates must post their resume at ISPOR's online eJOBS. Employers must have a job position posted on ISPOR's eJOBS to use the interview room **Room 202B (2nd Floor),** and must access the online scheduler to schedule interviews. Access to a candidate's database is included with the purchase of an eJOBS employment advertisement. For more information, please see ISPOR.org/employment or scan this code.

***INTERNET ACCESS***

Complimentary wireless internet access, provided by the Taipei International Convention Center, is available in meeting rooms and lobby areas. Please note, however, that connection speeds may vary due to the volume of users. Select the "TICC" network to use the Wi-Fi connection.

***CONFERENCE PROGRAM WARNING & USE OF PHOTOGRAPHIC IMAGES***

Please be advised that recording, by any means, of Conference presentations is prohibited. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will strictly enforce its rights as the exclusive licensee of all publication and reproduction rights to each presentation, and no presentation, in whole or in part, may be reproduced without approval from ISPOR.

Registration and attendance at the ISPOR 5th Asia-Pacific Conference constitutes an agreement by the registrant to ISPOR's use of their image (photograph and video) now and in the future.

---

**RESEARCH POSTER PRESENTATIONS**

Poster presentations will be on view in **Room 201 (2nd Floor).**

See pages 31-54 for Poster Presentation titles and authors.

Student Research Posters (all research posters where the first author is a student) are identified on the poster code.

<table>
<thead>
<tr>
<th>Poster Presentation Sessions</th>
<th>Poster Display Hours</th>
<th>Author Discussion Hour*</th>
<th>Presenter Set-up Time</th>
<th>Presenter Dismantle Time**</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SESSION I: Monday, 3 September</strong></td>
<td>8:30AM-8:30PM</td>
<td>7:00PM-8:00PM</td>
<td>8:15AM-8:30AM</td>
<td>8:30PM</td>
</tr>
<tr>
<td>PHP: HEALTH CARE USE &amp; POLICY STUDIES</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCV: CARDIOVASCULAR DISORDERS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGI: GASTROINTESTINAL DISORDERS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PII: INDIVIDUAL’S HEALTH</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRS: RESPIRATORY-RELATED DISORDERS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSS: SENSORY SYSTEMS DISORDERS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PKU: URINARY/RENAL DISORDERS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Presenters are required to be at their posters during the Poster Author Discussion Hour.

**Posters that are not removed during the scheduled dismantle times will be discarded.*

---

**SESSION II: Tuesday, 4 September**

See page 43

PCASE: HEALTH CARE DECISION-MAKER CASE STUDIES

PRM: RESEARCH ON METHODS

PCN: CANCER

PDB: DIABETES/ENDOCRINE DISORDERS

PIN: INFECTION

PMH: MENTAL HEALTH

PNC: CANCER

PD: DIABETES/ENDOCRINE DISORDERS

PM: INFECTION

PND: MUSCULAR-SKELETAL DISORDERS

PS: SYSTEMIC DISORDERS/CONDITIONS

<table>
<thead>
<tr>
<th>Poster Display Hours</th>
<th>Author Discussion Hour*</th>
<th>Presenter Set-up Time</th>
<th>Presenter Dismantle Time**</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30AM-5:00PM</td>
<td>11:15AM-12:15PM</td>
<td>8:15AM-8:30AM</td>
<td>5:00PM</td>
</tr>
</tbody>
</table>

---

---

---

---
CONFERENCE SUPPORTING INSTITUTIONS

Bureau of National Health Insurance  
National Yang-Ming University  
Chinese Pharmaceutical Association  
Pharmaceutical Society of Taiwan  
International Research-Based Pharmaceutical Manufacturers Association (Taiwan-IRPMA)  
Taipei Medical University  
National Evidence-based Healthcare Collaborating Agency (NECA)  
Taiwan Pharmacist Association  
National Taiwan University  
Taiwan Society of Health-System Pharmacists

CORPORATE SUPPORTERS

GOLD LEVEL

Novartis

BRONZE LEVEL

Bristol-Myers Squibb  
Pfizer

EVENT SUPPORTERS

Azmi Burhani Consulting  
Eli Lilly  
Janssen Asia Pacific  
Kantar Health  
Janssen Asia Pacific  
Johnson & Johnson  
ZRx Outcomes Research
ISPOR 5th ASIA-PACIFIC CONFERENCE
2-4 September 2012 • Taipei, Taiwan

SHORT COURSE PROGRAM
ECONOMIC METHODS
Introduction to Pharmacoeconomics
Room 201D (2nd Floor)
Faculty: David B. Matchar, MD, Professor & Director, Program for Health Services & Systems Research, Duke-NUS Graduate Medical School, Singapore
Course Description: This course is designed to teach clinicians and researchers the basics of pharmacoeconomic (economic) analysis in health care. This course will include the basic theory for determining cost and outcomes, the different types of costs and costing methods. Analysis methods to be discussed include cost-minimization, cost-benefit analysis, cost-utility (cost per QALY), cost-effectiveness, and incremental cost-effectiveness ratios (ICERS). The course will also highlight how analyses are framed, evaluated and reported. Finally, the course will outline challenges and considerations when utilizing pharmacoeconomics as a tool for developing clinical guidelines for health care systems.
Level: Introductory-Intermediate. This course is designed for those with limited experience with pharmacoeconomics.

MODELING METHODS
Introduction to Modeling Room 201F (2nd Floor)
Faculty: Shu-Chuen Li, PhD, MS, MBA, Chair & Head, Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, NSW, Australia
Course Description: This course will introduce pharmacoeconomic modeling techniques such as decision analytic modeling, Markov modeling, discrete event models, and other modeling techniques and their appropriate usages including a review of the ISPOR Modeling Good Research Practices. Examples will be presented using Microsoft Excel, with add on simulation software. This course will include practical steps in the selection of models and options in modeling of data inputs.
Level: Introductory-Intermediate. This course is recommended as a prerequisite to the ISPOR short course "Applied Modeling".

OBSERVATIONAL DATA METHODS
Introduction to Retrospective Database Design and Analysis Room 201A (2nd Floor)
Faculty: Jeff J. Guo, PhD, B. Pharm, Professor, Division of Pharmacy Practice & Administrative Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA; Hui-Min (Grace) Wu, PhD, Researcher, Division of HTA, Center for Drug Evaluation, Taipei, Taiwan; Hong Li, PhD, MPH, Group Director, Global Health Economics and Outcomes Research (GHEOR), Bristol-Myers Squibb, Wallingford, CT, USA and Adjunct Associate Professor, University of Cincinnati Medical Center, Cincinnati, OH, USA, Duke-National University of Singapore Graduate Medical School, Singapore
Course Description: Retrospective studies require strong principles of epidemiologic study design and complex analytic methods to adjust for bias and confounding. This course will provide an overview of fundamental design strategies, analytic techniques and specific best practices to improve causal inference in studies using retrospective databases. Specific topics to be covered at an introductory level include: measurement of exposure and outcome, causal graphs, new user study design, measures of comorbidity, the use of stratification analysis before multivariable modeling, multivariable regression including Cox proportional hazards survival analysis, model performance and diagnostic testing, propensity scoring, instrumental variable and structural modeling techniques including marginal structural models.
Level: Introductory. This course is designed for those with little experience with database analysis.

USE OF PHARMAECONOMIC / ECONOMIC / OUTCOMES RESEARCH INFORMATION
New! Introduction to Health Technology Assessment Room 201BC (2nd Floor)
Faculty: Uwe Siebert, MD, MPH, MSc, ScD, Professor of Public Health & Chair, Department of Public Health and Health Technology Assessment, University for Health Sciences, Medical Informatics and Technology, Hall/Innsbruck, Austria and Adjunct Professor of Health Policy and Management, Center of Health Decision Science, School of Public Health, Harvard University, Boston, MA, USA; Yen-Huei (Tony) Tarn, PhD, MS, Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan; Jeonghoon Ahn, PhD, MA, Senior Director, Office of Health Services Research, National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea
Course Description: This course will introduce the key elements, methods and terms of health technology assessment (HTA), and provide an overview of basic HTA disciplines including benefit assessment (biostatistics, clinical epidemiology, patient-relevant outcomes, risk-benefit assessment), economic evaluation (costing, cost-effectiveness analysis, pharmacoeconomic modeling, budget impact analysis, resource allocation), ethical, legal and social implications. Using real world HTA examples of drugs and devices, this course will review the practical steps involved in developing and using HTA reports in different countries and their health care systems. Group discussion will focus on the perspectives of different stakeholders and the implementation of HTA in decision-making.
Level: Introductory. This course is suitable for those with little or no experience with HTA.

PATIENT-REPORTED OUTCOMES PREFERENCE-BASED METHODS
Introduction to Patient-Reported Outcomes Room 103 (1st Floor)
Faculty: Bruce Crawford, MA, MPH, Senior Vice President, Adelphi Values, Tokyo, Japan; Kaiping (Grace) Yao, PhD, Professor, Division of Psychometrics, Department of Psychology, National Taiwan University, Taipei, Taiwan
Course Description: Definitions and concepts, methodologies, and practical methods for measuring patient-reported outcomes will be presented. The value of patient-reported outcomes assessment will be discussed. A strategy to aid in selecting appropriate instruments and the translation processes will be presented. Instrument development and validation will be discussed using practical examples and exercises, including the ISPOR Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures.
Level: Introductory-Intermediate. This course is designed for those with little experience with quality of life/PRO studies.
OUTCOMES RESEARCH METHODS

Meta-Analysis and Systematic Literature Review

Room 201E (2nd Floor)

Faculty: Nathorn Chaiyakunapruk, PharmD, PhD, Director of Center for Pharmaceutical Outcomes Research and Associate Professor of Pharmacy, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand

Course Description: Meta-analysis may be defined as the statistical analysis of data from multiple studies for the purpose of synthesizing and summarizing results, as well as for quantitatively evaluating sources of heterogeneity and bias. A systematic literature review often includes meta-analysis and involves an explicit, detailed description of how a review was conducted. This course highlights and expounds upon four key areas: 1) impetus for meta-analysis and systematic reviews, 2) basic steps to perform a quantitative systematic review, 3) statistical methods of combining data, and 4) an introduction to methods for indirect comparisons. The material includes practical examples from the published literature relevant to pharmacoeconomic and PRO research. This course is designed for those with little experience with meta-analysis and includes interactive exercises.

Level:Introductory-Intermediate. This course requires basic understanding of statistical method and is recommended as a prerequisite to the ISPOR short course "Network Meta-Analysis and Indirect Treatment Comparisons"

ECONOMIC METHODS

Transferability of Cost-Effectiveness Data between Countries

Room 201A (2nd Floor)

Faculty: Michael F. Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Raoh-Fang (Jasmine) Pwu, PhD, Director, Division of Health Technology Assessment, Center for Drug Evaluation and Adjunct Professor, Taipei Medical University, Taipei, Taiwan

Course Description: This course will discuss factors that make economic data more difficult than clinical data to adapt from other countries and the evidence on the variability of cost-effectiveness results across countries. Potential methods to provide solutions will be reviewed and their pros and cons will be discussed, including the ISPOR Good Research Practices for transferability of economic evaluations across jurisdictions. Finally, emerging international guidance for dealing with issues of transferability will be discussed.

Level: Intermediate. This course is designed for those with basic understanding of economic evaluations of health care and experience in the critical assessment of cost-effectiveness studies.

SUNDAY, 2 SEPTEMBER

AFTERNOON COURSES (1:00PM-5:00PM)

ECONOMIC METHODS

ECONOMIC METHODS

Impact of Cost of Illness

Room 103 (1st Floor)

Faculty: Sean D. Sullivan, PhD, Professor of Pharmacy and Public Health, Director, Pharmaceutical Outcomes Research and Policy Program and Associate Dean for Research, School of Pharmacy, University of Washington, Seattle, WA, USA; Wen-Yi Shau, PhD, Principal Researcher, Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan

Course Description: This course will describe methods to determine the costs associated with a health condition and the budget impact of new technologies for that condition. Participants will learn the different types of analyses needed to complete a budget impact analysis, how to distinguish between static and dynamic budget impact models, and how to design a study to estimate the budget impact of a new health care intervention. The ISPOR Good Research Practice Guidance on Budget Impact Analysis will be discussed, along with common pitfalls of budget impact models.

Level: Intermediate. This course is designed for those with some experience with pharmacoeconomic analysis.

ECONOMIC METHODS

New! Statistical Considerations in Health Economic Evaluations

Room 201D (2nd Floor)

Faculty: Jalsa A. Doshi, PhD, Associate Professor of Medicine, Director, Economic Evaluations Unit, Center for Evidence-based Practice and Director, Value-Based Insurance Design Initiatives, Center for Health Incentives, University of Pennsylvania, Philadelphia, PA, USA; Chee-Jen Chang, PhD, Director, Clinical Informatics and Medical Statistics Research Center and Professor, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan

Course Description: Adoption and diffusion of new medical treatments depend increasingly on robust analysis of costs and cost-effectiveness (CEA). This course will discuss design issues for the collection of primary economic data as well as statistical considerations. Participants will be able to design economic evaluations in clinical trials, evaluate patient-level costs and evaluate sampling uncertainty in cost-effectiveness analysis. The ISPOR Good Research Practices on CEA alongside Clinical Trials will also be discussed.

Level: Introductory-Intermediate. This course is designed for those with a basic understanding of statistics.

MODELING METHODS

Applied Modeling

Room 201E (2nd Floor)

Faculty: Mark Roberts, MD, MPP, Professor & Chair, Health Policy & Management, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, USA; Hsing Luh, PhD, Professor, Department of Mathematical Sciences, National Chengchi University, Taipei, Taiwan

Course Description: This course is an introduction to the use of software for the creation and analysis of cost-effectiveness decision models. Participants will learn how to use TreeAge Pro software to develop and analyze a simple decision tree, create a cost effectiveness model that incorporates cost and utilities, extend the model to incorporate time-vary events through the application of state-transition (Markov) processes, and conduct one-way, two-way, and probabilistic sensitivity analyses. This course will provide hands-on experience through practical tutorials.

Level: Intermediate-Advanced. This course is suitable for those who are familiar with the various modeling methods and the ISPOR short course "Introduction to Modeling" is recommended as a prerequisite for this course. All participants must bring a Windows laptop computer with a copy of TreeAge Pro Suite installed and running. You will be provided download and installation instructions when you pre-register for the course.

Sunday Afternoon Coffee Break

Sponsored by Kantar Health
USE OF PHARMACOECONOMIC / ECONOMIC / OUTCOMES RESEARCH INFORMATION

Pharmaceutical/Biotech Pricing & Reimbursement Methodologies  
**Room 201BC (2nd Floor)**

Faculty: Jack M. Mycka, Global President & CEO, MME LLC, Montclair, NJ, USA; Shannian Hu, MD, MSc, Professor, School of Public Health, Fudan University, Shanghai, China; Manny Papadimitropoulos, PhD, Director, Outcomes Research Emerging Markets, Eli Lilly Canada, Inc.

**Course Description:** This course will give participants a basic understanding of the key terminology and issues involved in pricing decisions and the principles of reimbursement methodologies. It covers the tools to document product value, the role of pharmacoeconomics and the differences in payment systems that help pricing decisions. Recent pharmaceutical spending patterns, trends and cost-containment measures will also be discussed, taking into account the wider policy context. The pricing and reimbursement systems in Taiwan, South Korea, Thailand, China Mainland and other Asian countries/regions will be discussed in-depth. The case from Australia will be introduced as well.

**Level:** Introductory-Intermediate. This introductory course is designed for those with limited experience in pharmaceutical pricing and reimbursement.

OUTCOMES RESEARCH METHODS

New! Network Meta-Analysis and Indirect Treatment Comparisons  
**Room 201F (2nd Floor)**

Faculty: Shannon Cope, MSc, Senior Research Manager, MAPI Consultancy, Boston, MA, USA; Nathorn Chaiyakunapruk, PharmD, PhD, Director of Center for Pharmaceutical Outcomes Research and Associate Professor of Pharmacy, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand; Jeonghoon Ahn, PhD, MA, Senior Director, Office of Health Services Research, National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea

**Course Description:** When head to head randomized controlled trials are absent, network meta-analysis offers a quantitative method of integrating all the data from all the available comparisons while indirect treatment comparisons can be conducted and provides useful evidence. In this course, the fundamentals and concepts of network meta-analysis will be presented. ISPOR Good Research Practices for Conducting and Interpreting Network Meta-Analysis and Indirect Treatment Comparisons will also be presented. Participants will be able to understand the concepts and assumptions of network meta-analysis (indirect and mixed treatment comparisons), such as heterogeneity, transitivity, and consistency, critically analyze the results of network meta-analysis, recognize the statistical models used to explore heterogeneity and inconsistency, and know that WinBUGS and SAS can be used to perform network meta-analysis. A practical example of indirect treatment comparison in the Asia context will be introduced.

**Level:** Intermediate. This course is designed for those with some understanding of meta-analysis, and the ISPOR short course “Meta-Analysis and Literature Review” is recommended as a prerequisite for this course.

ISPOR Distance Learning Program (iDLP)

The ISPOR Distance Learning Program (iDLP) is designed to provide knowledge and skills on pharmacoeconomic and outcomes research topics (clinical, economic, and patient-reported outcomes). The iDLP is an educational tool for students, clinicians, researchers, public and private decision-makers, and drug, medical device, and diagnostic industry stake-holders. The iDLP is also a valuable information resource in countries where the need for pharmacoeconomics and outcomes research and its use in health technology assessment is emerging.

ISPOR Distance Learning Program Modules

Outcomes Research Methods  
Economic Methods  
Modeling Methods  
Patient-Reported Outcomes  
Observational Data Methods  

DLP Modules Available in: English, Chinese, Portuguese, & Spanish

Translations in Progress: Arabic, Bosnian, Polish, Russian, Serbian, Turkish, & Ukrainian

The iDLP can be found at www.ispor.org under the “Education” tab.
ISPOR 5th ASIA-PACIFIC CONFERENCE
2-4 September 2012 • Taipei, Taiwan

PROGRAM & SCHEDULE OF EVENTS
SUNDAY, 2 SEPTEMBER

8:00AM-12:00PM  PRE-CONFERENCE MORNING SHORT COURSES  Short Course registration required
(See page 13 for Short Course descriptions)

1:00PM -5:00PM  PRE-CONFERENCE AFTERNOON SHORT COURSES  Short Course registration required
(See page 13 for Short Course descriptions)

5:15PM-6:15PM  EDUCATIONAL SYMPOSIUM  Room 102 (1st Floor)
(See page 62 for Symposium description)
CONDUCTING REAL-WORLD NON-INTERVENTIONAL STUDIES IN MULTIPLE COUNTRIES: WHY, WHEN AND HOW?
Sponsored by Novartis

6:30PM-7:30PM  EDUCATIONAL SYMPOSIUM  Room 102 (1st Floor)
(See page 62 for Symposium description)
HEALTH ECONOMICS AND OUTCOMES RESEARCH IN PERSONALIZED MEDICINE
Sponsored by Pfizer

7:45PM-8:45PM  EDUCATIONAL SYMPOSIUM  Room 102 (1st Floor)
(See page 62 for Symposium description)
INNOVATION: WHAT IS IT, WHO SHOULD PAY AND WHAT IS A FAIR PRICE?
Sponsored by GlaxoSmithKline

9:00PM-11:00PM  WELCOME RECEPTION  Jade (2nd Floor)
All attendees welcome! Network with colleagues at this Welcome Reception. Drinks and appetizers provided, reception features traditional live music.
Reception supported by the Taipei City Government and the ISPOR Taiwan Chapter

MONDAY, 3 SEPTEMBER

8:30AM-8:30PM  RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I  Room 201 (2nd Floor)
(See pages 31-54 for Research Poster Presentations)

8:30AM-9:00AM  WELCOME  Room 101 (1st Floor)
Chinese/English translation

WELCOME FROM PROGRAM COMMITTEE CO-CHAIRS
Yen-Huei (Tony) Tarn, MS, PhD, Program Committee Co-Chair and Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan
(See pages 65-68 for biographical information)

Chee-Jen Chang, PhD, Program Committee Co-Chair, Director, Clinical Informatics and Medical Statistics Research Center and Professor, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan
(See pages 65-68 for biographical information)

WELCOME FROM ISPOR ASIA CONSORTIUM EXECUTIVE COMMITTEE CHAIR
Surachat Ngorsuraches, PhD, RPh, 2012-2014 ISPOR Asia Consortium Executive Committee Chair and Associate Professor, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand
(See pages 65-68 for biographical information)

WELCOME FROM ISPOR PRESIDENT
Deborah Marshall, PhD, MHS, 2012-2013 ISPOR President, Research Chair, Health Services and Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary and Director, Health Technology Assessment, Alberta Bone and Joint Health Institute, Calgary, AB, Canada
(See pages 65-68 for biographical information)
WELCOME FROM TAIPEI MAYOR
Lung-Pin Hau, PhD, Mayor of Taipei, Taipei, Taiwan

9:00AM-9:15AM OPENING SPEECH Room 101 (1st Floor)
Chinese/English translation
THE FUTURE OF TAIWAN HEALTH CARE SYSTEM AND POLICIES
Wen-Ta Chiu, MD, PhD, Minister of Health, Department of Health, Taipei, Taiwan

9:15AM-10:45AM FIRST PLENARY SESSION Room 101 (1st Floor)
Chinese/English Translation
HEALTH TECHNOLOGY ASSESSMENT IN THE SIGNIFICANTLY EVOLVING HEALTH CARE SYSTEMS IN ASIA
(See pages 65-68 for biographical information)
Health technology assessment (HTA) is a multidisciplinary process that summarizes information about the medical, social, economic and ethical issues related to the use of a health technology in a systematic, transparent, unbiased, robust way. To ensure the HTA process is successful, a health system needs the infrastructure and human capacity, adequate data sources, PE/HTA guidelines, and an understanding of the methods used in HTA. In Asia, where health systems are significantly changing and resources are severely limited, conducting or evaluating a health technology in Asia is a real challenge. This session will discuss the key building blocks in the development of an HTA process in the Asian context and the role of HTA in improving the health care systems in Asia.

Moderator:
Chee-Jen Chang, PhD, Director, Clinical Informatics and Medical Statistics Research Center and Professor, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan

Speakers:
Tzou-Yien Lin, MD, Deputy Minister, Department of Health, Executive Yuan (Cabinet), Taipei, Taiwan
Kook-hyun Cho, MA, Managing Executive Director, National Health Insurance Corporation, Seoul, South Korea
Jie Chen, PhD, Director, Key Lab of Health Technology Assessment, Ministry of Health, Director, Center for Health Technology Assessment, Shanghai Municipal Bureau and Professor, School of Public Health, Fudan University, Shanghai, Mainland China

Panelists:
Donald D. Yin, PhD, Associate Vice President & Head, Global Health Outcomes, Merck & Co., Inc., Whitehouse Station, NJ, USA
Manny Papadimitropoulos, PhD, Director, Outcomes Research, Emerging Markets, Eli Lilly and Company, Toronto, ON, Canada

10:45AM-11:00AM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I Room 201 (2nd Floor)
(See pages 31-54 for Research Poster Presentations)

11:00AM-12:00PM ISSUE PANELS & WORKSHOPS – SESSION I
Room 101 (1st Floor)

IP1: HOW TO HARMONIZE HTA AND VALUE FOR INNOVATION? Room 101 (1st Floor)
Chinese/English translation
Moderator: Sang-il Lee, PhD, MD, MPH, President, Korea Association of Health Technology Assessment (KAHTA), University of Ulsan College of Medicine, Seoul, South Korea
Panelists: Su-Kyong Ko, PhD, Market Access Director, Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea; Eui Kyung Lee, PhD, Professor of Pharmaceutical Policy & Outcomes Research, School of Pharmacy, Sungkyunkwan University, Seoul, South Korea; Jeonghoon Ahn, PhD, MA, Senior Director, Office of Health Services Research, National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea

W1: USING INDIVIDUAL SIMULATION TO FORECAST DISEASE EPIDEMIOLOGY AND BURDEN OF ILLNESS North Lounge (3rd Floor)
Discussion Leaders: Feng Pan, PhD, Research Scientist, Health Economics, United BioSource Corporation, Bethesda, MD, USA; Thitima Kongnakorn, PhD, Senior Research Associate, Health Economics, United BioSource Corporation, Bangkok, Thailand; John Cai, PhD, Professor, China Europe International Business School, Shanghai, China

W2: INTEGRATION OF SURVIVAL WITH QUALITY OF LIFE FOR OUTCOMES RESEARCH: SHARING OF A FREE SOFTWARE Room 105 (1st Floor)
Discussion Leaders: Jung-Der Wang, MD, ScD, Professor & Chair, Department of Public Health, National Cheng Kung University College of Medicine, Tainan, Taiwan; Jing-Shiang Hwang, PhD, Deputy Director, Institute of Statistical Science, Academia Sinica, Taipei, Taiwan; Chi-Tai Fang, MD, PhD, Associate Professor, Institute of Epidemiology and Preventive Medicine, National Taiwan University College of Public Health, Taipei, Taiwan; Mei-Chuan Hung, MPH, PhD Student, Institute of Occupational Medicine and Industrial Hygiene, College of Public Health, National Taiwan University, Taipei, Taiwan
W3: ISSUES IN ADAPTING GLOBAL HEALTH ECONOMIC MODELS TO EMERGING MARKETS: A CONVERSATION WITH HEALTH AUTHORITIES, PHARMACEUTICAL INDUSTRY AND CONSULTANTS IN ASIA-PACIFIC

Discussion Leaders: Renee J.G. Arnold, PharmD, RPh, Principal, HEOR, IMS Health, New York, NY, USA; Jianwei Xuan, MD, PhD, Senior Director & Team Leader, Pfizer, New York, NY, USA; Shanlian Hu, MD, MSc, Professor of Health Economics & Director, Center for Health Development Research, Shanghai Bureau of Health, School of Public Health, Fudan University, Shanghai, China; Kenneth K.C. Lee, MPhil, PhD, Professor of Pharmacy, Pharmacy; School of Medicine and Health Sciences, Monash University Sunway Campus, Bandar Sunway, Malaysia

W4: CONDUCTING ONCOLOGY HEALTH SERVICES RESEARCH AND COMPARATIVE EFFECTIVENESS RESEARCH USING LARGE CLAIM DATABASES: TAIWANESE AND UNITED STATES EXPERIENCES

Discussion Leaders: Fei-Yuan Hsiao, PhD, Assistant Professor, Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei, Taiwan; Ya-Chen Tina Shih, PhD, Associate Professor, Section of Hospital Medicine, Department of Medicine and Director, Program in the Economics of Cancer, The University of Chicago, Chicago, IL, USA; Chun-Ru Chien, PhD, MD, Director, China Medical University Hospital, Taichung, Taiwan; C. Daniel Mullins, PhD, Professor, Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA

12:00PM-3:00PM LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I

Room 201 (2nd Floor)

12:30PM-1:30PM EDUCATIONAL SYMPOSIUM Room 101 (1st Floor)

Chinese/English translation

CLINICAL ENDPOINTS: FINAL VERSUS SURROGATE ENDPOINT - IMPLICATIONS AND RELEVANCE FROM A PAYER, PHYSICIAN AND PATIENT PERSPECTIVE

Sponsored by Eli Lilly and Company

1:45PM-2:45PM EDUCATIONAL SYMPOSIUM Room 101 (1st Floor)

Chinese/English translation

REAL-WORLD EVIDENCE: MEETING THE CHALLENGE OF STAKEHOLDER NEEDS FOR DEMONSTRATING VALUE IN ASIA

Sponsored by IMS Health

3:00PM-4:30PM WELCOME & SECOND PLENARY SESSION Room 101 (1st Floor)

Chinese/English Translation

INVOLVING PATIENTS & HEALTH CARE PRACTITIONERS IN HEALTH CARE DECISIONS: LEARNING FROM EACH OTHER

Health technology assessment (HTA) in Asia is a process that mainly involves specialized experts from academia, industry, and government agencies. One common observation across the region is the limited or lack of involvement by patients or health care practitioners in the process. If the HTA process is to actively engage all key stakeholder groups, patients and health care practitioners should be included. For example, the Australian Patients Association, UK’s NICE Citizens’ Council, and International Alliance of Patients’ Organizations provide valuable input on contentious subjects and collectively lobby for patient’s rights, including equity and access to health care technology. In this session, international experience on how the views of patients and health care practitioners are incorporated into HTA and health care coverage decisions will be shared, and how this experience can be adapted in Asia will be discussed and debated.

Moderator: Yen-Huei (Tony) Tarn, PhD, MS, Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan

Speakers:
Sir Andrew Dillon, Chief Executive, National Institute for Health and Clinical Excellence (NICE), London, UK
Durhane Wong-Rieger, PhD, Chair, International Alliance of Patients’ Organizations, London, UK
Stephen Mason, LLB, BComm, DipCM, FCPA, FCSA, JP, Chief Executive Officer, Australian Patients Association, Melbourne, VIC, Australia

Panelists:
Mao Sheen, MSc, MA, Director, Department of Medical Review and Pharmaceutical Benefit, Bureau of National Health Insurance, Taipei, Taiwan
Tae-jin Lee, PhD, Associate Professor, School of Public Health, Seoul National University, Seoul, South Korea
ISPOR 5th ASIA-PACIFIC CONFERENCE
2-4 September 2012 ■ Taipei, Taiwan

PROGRAM & SCHEDULE OF EVENTS: MONDAY, 3 SEPTEMBER continued

4:30PM-4:45PM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
Room 201 (2nd Floor)
(See pages 31-34 for Research Poster Presentations)

4:45PM-5:45PM RESEARCH PODIUM PRESENTATIONS – SESSION I
(Page numbers shown to the left refer to the abstract in this Program & Schedule of Events)

COST-EFFECTIVENESS STUDIES Room 103 (1st Floor)
Moderator: Syed Mohamed Aljunid, MD, MSc, PhD, FAMM, Professor of Health Economics, and Senior Research Fellow, United Nations University-International Institute of Global Health (UNU-IIGH), National University of Malaysia, Kuala Lumpur, Malaysia

4:45PM-5:00PM pg70
CE1 THE COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) IN TAIWAN
Wu DBC, Chang CJ, Chen L1, Fang HCH1, Roberts CS1, National Yang-Ming University, Taipei, Taiwan; 2Chang Gung University, Tao-Yuan, Taiwan; 3Pfizer, New Taipei City, Taiwan; 4Pfizer, New York, NY, USA

5:00PM-5:15PM pg70
CE2 COST-EFFECTIVENESS OF THE REAL-WORLD USE OF NUCLEIC ACID TEST SCREENING TO DONATED BLOOD FOR HEPATITIS B, HEPATITIS C, AND HUMAN IMMUNODEFICIENCY VIRUS: EXPERIENCE FROM TAIWAN, A COUNTRY WITH A HIGH PREVALENT OF HEPATITIS B AND C INFECTIONS
Wu GHH1, Wang YC1, Lin SJ2, Lin KS2, 1Center for Drug Evaluation, Taipei, Taiwan; 2Taiwan Blood Services Foundation, Taipei, Taiwan

5:15PM-5:30PM pg70
CE3 HYPERBARIIC OXYGEN THERAPY FOR THE TREATMENT NON-NEUROLOGICAL SOFT TISSUE RADIATION INJURIES: A COST-EFFECTIVENESS ANALYSIS
Cronin P1, Hoggan B1, Goodall S1, Cameron A1, University of Technology, Sydney, Broadway, NSW, Australia; 2Royal Australasian College of Surgeons, Adelaide, SA, Australia

5:30PM-5:45PM pg70
CE4 COST-EFFECTIVENESS OF BABIGRAMAN COMPARED TO GENOTYPE-GUIDED WARFARIN DOSING FOR STROKE PROPHYLAXIS IN ATRIAL FIBRILLATION PATIENTS
Lim KJ1, Tan DSY2, Wee HL1, 1National University of Singapore, Singapore; 2Khoo Teck Puat Hospital, Singapore

CANCER OUTCOMES STUDIES North Lounge (3rd Floor)
Moderator: Zhongyun Zhao, PhD, Directo, Global Health Economics, Amgen Inc., Thousand Oaks, CA, USA

4:45PM-5:00PM pg71
CN1 STATINS AND THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HEPATITIS B VIRUS INFECTION
Tsan YT1, Lee CH1, Wang JD1, Chen PC1, 1National Taiwan University, Taipei, Taiwan; 2Department of Occupational Medicine, Ton Yen General Hospital, Hsin-Chu County, Taiwan; 3Hsinchu County, Taiwan; 4National Cheng Kung University College of Medicine, Tainan, Taiwan; 5College of Public Health, National Taiwan University, Taipei, Taiwan

5:00PM-5:15PM pg71
CN2 HOW EARLY-STAGE NON-PERSISTENCE AND NON-ADHERENCE TO ADJUVANT HORMONAL THERAPY ASSOCIATED WITH POSTMENOPAUSAL BREAST CANCER MORTALITY IN TAIWAN
Hsieh KP1, Chen LC1, Chang CS1, Yang YH1, 1Kaohsiung Medical University, Kaohsiung, Taiwan; 2University of Nottingham, Nottingham, UK

5:15PM-5:30PM pg71
CN3 COST-EFFECTIVENESS ANALYSIS OF TREATMENTS IN ADULT CANCER PATIENTS WITH LOW RISK FEBRILE NEUTROPENIA IN THAILAND
Jandee O1, Permsuwan U1, Lopburi Cancer Center, Lopburi, Thailand; 2Chiang Mai University, Chiang Mai, Thailand

5:30PM-5:45PM pg71
CN4 INPATIENT TREATMENT PATTERNS AND HEALTHCARE EXPENDITURES FOR HEPATOCELLULAR CARCINOMA AMONG POPULATION WITH BREAST CANCER MORTALITY IN TAIWAN
Xiong X1, Li J1, Qiao Y1, Yu Z1, Zhang Y1, Wei Meng4, 1China Health Insurance Research Association, Beijing, China; 2Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; 3Beijing Brainpower Pharma Consulting Co. Ltd., Beijing, China; 4Sino-American Shanghai Squibb Pharmaceuticals Ltd., Shanghai, China

DIABETES OUTCOMES STUDIES Room 105 (1st Floor)
Moderator: Ashoke Bhattacharjya, PhD, Executive Director, Global Economic Affairs, Johnson & Johnson, New Brunswick, NJ, USA

4:45PM-5:00PM pg72
DB1 EPIDEMIOLOGY, TREATMENT AND ECONOMIC BURDEN OF TYPE 2 DIABETES MELLITUS WITH NEPHROPATHY COMPLICATIONS IN CHINA
Huang YY1, Fan WJ1, Zuo JJ1, Zhan L1, Chen W1, 1School of Public Health, Fudan University, Shanghai, China; 2Boehringer Ingelheim Shanghai Pharmaceuticals Co. Ltd., Shanghai, China; 3Fudan University, Shanghai, China

5:00PM-5:15PM pg72
DB2 VITAMIN D DEFICIENCY AND DIABETES: PERCEPTIONS OF PHARMACISTS AND PHYSICIANS
Jalundhwala F1, Jamdee O1, Lopburi Cancer Center, Lopburi, Thailand; 2University of Hong Kong, Hong Kong, Hong Kong; 3Hong Kong Polytechnic University, Hong Kong; 4Hong Kong Hospital Authority, Hong Kong

5:15PM-5:30PM pg72
DB3 INDIRECT TREATMENT COMPARISON (ITC) OR COST EFFECTIVENESS ANALYSIS (CEA): A STUDY
Kim H1, Gurin L1, Liew D1, 1University of Melbourne, Parkville, Victoria, Australia; 2University of Melbourne, Carlton, Victoria, Australia

5:30PM-5:45PM pg72
DB4 SCREENING FOR DIABETIC RETINOPATHY IN HONG KONG: IS INVERSE CARE LAW OPERATING?
Lian JX1, McGhee SM1, Chan CKW1, Wong SH1, Yap KHF1, Lam LK1, Hedley AJ1, Gangwani RA1, Chu WS1, 1University of Hong Kong, Hong Kong; 2Hong Kong Polytechnic University, Hong Kong; 3Hong Kong Hospital Authority, Hong Kong

HEALTH CARE USE AND POLICY STUDIES Room 101 (1st Floor)
Moderator: Surachet Ngsurachais, PhD, RPh, Associate Professor, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hatyai, Songkhla, Thailand

4:45PM-5:00PM pg72
HC1 PRICE PREMIUM FOR INNOVATION? COST CALCULATION METHOD IN JAPAN VS. COST UTILITY ANALYSIS IN SOUTH KOREA
Tan S1, Lopresti M1, Latif F1, Wasserman M1, 2Double Helix Consulting, Asia-Pacific, Singapore, Singapore; 3Goddard Health, LLC, Tokyo, Tokyo, Japan; 4Double Helix Consulting, London, UK
RESEARCH ON METHODS STUDIES

**Moderator:** Michael Ortiz, MSc, PhD, RPh
Conjoint Associate Professor, University of New South Wales, Artarmon, NSW, Australia

**4:45PM-5:00PM**

**HC2** A REVIEW OF ECONOMIC EVALUATIONS OF NEW DRUGS PRICED BY THE SIMILAR DRUG COMPARISON METHOD IN JAPAN: DID COST EFFECTIVENESS RESULTS JUSTIFY PREMIUMS?  
Kasai M, Shiroya T, Ikeda S, 1Graduate School, International University of Health and Welfare, Tokyo, Japan, 2Ritsumeikan University, Kusatsu, Shiga, Japan, 3International University of Health and Welfare, Ohtawaara-city, Tochigi, Japan

**5:15PM-5:30PM**

**HC3** THE PROCESS OF UPDATING THE ITEMS OF NATIONAL HEALTH INSURANCE BENEFITS SCHEDULE IN TAIWAN: IS IT FAIR AND LEGITIMATE?  
Lin CW, I-Shou University, Kaohsiung, Taiwan

**5:30PM-5:45PM**

**HC4** TAPPING INTO THE ASIAN PHARMACEUTICAL MARKET: GLOBAL FIRMS GO LOCAL?  

**5:00PM-5:15PM**

**ME1** COMPARISON OF THE MEASUREMENT PROPERTIES BETWEEN THE 5-LEVEL EQUROOL GROUP’S 5-DIMENSION (EQ-5D-5L) QUESTIONNAIRE AND THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY – BREAST (FACT-B) IN ASIAN BREAST CANCER PATIENTS  
Cheung YB, Lee CF, Luo N, Ng R, Wong NS, Yap YS, Lo SK, Chia J, Yee A, Krishna L, Wong CF, Goh C, 1Duke - National University of Singapore Graduate Medical School, Singapore, Singapore, 2Singapore Clinical Research Institute, Singapore, 3National University of Singapore, Singapore, 4National Cancer Centre, Singapore

**6:00PM-6:15PM**

**ME2** VALIDATION OF THE KIDNEY DISEASE AND QUALITY OF LIFE QUESTIONNAIRE (KDOQI-36) IN HAEMODIALYSIS PATIENTS IN SINGAPORE  
Yan Y, Wong VW, Joshi VD, Luo N, Saw S, Hock S, School of Public Health, National University of Singapore, Singapore, 2Center for Health Services Research, Singapore Health Services, Singapore, Singapore, 3National University of Singapore, Singapore

**6:15PM-6:30PM**

**ME3** CENSOR ADJUSTED NET MONETARY BENEFIT OF ANTI-HCV THERAPY IN THE VARIETY OF REAL-WORLD TREATMENT SETTING  
Norman R, Viney R, Braizer J, Burgess L, Cronin P, King M, Ratcliffe J, Street DJ, 1University of Technology, Sydney, NSW, Australia, 2University of Sheffield, Sheffield, South Yorkshire, UK, 3University of Sydney, Sydney, Australia, 4Flinders University, Adelaide, SA, Australia

**6:45PM-7:00PM**

**ME4** USING DISCRETE CHOICE EXPERIMENTS TO VALUE HEALTH STATES FOR ECONOMIC EVALUATION – THE SF-6D IN AUSTRALIA  
Hou CT, Kauf T, Akiquisun Chang Gung Memorial Hospital, Kaohsiung, Taiwan, 1University of Florida, Gainesville, FL, USA

**CLINICAL OUTCOMES STUDIES**

**Room 105 (1st Floor)**

**Moderator:** Boxiang Tang, MD, PhD, Senior Director, Outcomes Research, Pfizer Inc., New York, NY, USA

**6:00PM-6:15PM**

**CL1** A NOVEL METHOD FOR CALCULATING PREVALENCE OF MULTIPLE SCLEROSIS IN AUSTRALIA  
Palmer AJ, Hillkins PL, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia

**6:15PM-6:30PM**

**CL2** USEFULNESS OF DAYS LOST DUE TO DISABILITY AS A NEW METHOD IN MEASURING BURDEN OF ADVERSE DRUG REACTIONS  
Thomas D, Vijaya Raghavan C, Padmanabha Reddy Y, Kumar BM, 1RDT/RIPER, Antanapah, AP, India, 2PSG College of Pharmacy, Coimbatore, TN, India, 3JIT Islam College of Pharmacy, Kozhikode-Keral, India

**6:30PM-6:45PM**

**CL3** ANTICOAGULATION CONTROL OF A PHARMACIST MANAGED ANTICOAGULATION CLINIC IN A NATIONAL REFERRAL CENTRE IN MALAYSIA  
Thanimaiyal S, Shafie AA, Ahmad Hassali MA, Sinnadurai J, 1Universiti Sains Malaysia, Penang, Malaysia, 2Hospital Kuala Lumpur, Kuala Lumpur, Wilayah Persekut, Malaysia

**6:45PM-7:00PM**

**CL4** DRUG SWITCHING EVENTS AMONG USERS OF NSAIDS WITH OR WITHOUT GASTRO-PROTECTIVE DRUGS AS AN EARLY DETERMINANT OF DISSATISFACTION FROM GASTROINTESTINAL ADVERSE EVENTS  
Chen JJ, Huang YB, Wen YH, Chen SH, Yang YH, Kaohsiung Medical University, Kaohsiung, Taiwan

**CARDIOVASCULAR DISORDERS OUTCOMES STUDIES**

**Room 105 (2nd Floor)**

**Moderator:** Liang Sh, MS, PhD, Associate Professor, Department of Health Systems Management, TELU University, New Orleans, LA, USA

**6:00PM-6:15PM**

**CV1** STATIN PRESCRIPTION IN AUSTRALIA: A COMPARISON OF DIFFERENCES IN PRESCRIBED DOSES AND POTENTIAL IMPACT ON HEALTH OUTCOMES  
Ademi Z, Liew D, 1University of Melbourne, Melbourne, Australia, 2University of Melbourne, Parkville, Victoria, Australia

**6:15PM-6:30PM**

**CV2** AGE, DEMENTIA, AND EVIDENCE-BASED MEDICATION USE AFTER ADMISSION FOR ACUTE CORONARY SYNDROME  
Lin CF, Hisao FY, Wu FL, Bai CH, Gau CS, Shen LJ, 1National Taiwan University, Taipei, Taiwan, 2Taipei Medical University and Shin Kong WHS Memorial Hospital, Taipei, Taiwan

**6:30PM-6:45PM**

**CV3** REAL-WORLD CHARACTERIZATION OF HYPERTENSION PATIENTS IN JAPAN: A 1-YEAR OVERVIEW  
Crawford B, Ong SH, Falvey H, 1Adelphi Values, Tokyo, Japan, 2Novartis Pharma AG, Basel, Switzerland

**6:45PM-7:00PM**

**CV4** ASSOCIATION BETWEEN KNOWLEDGE AND HEALTH RELATED QUALITY OF LIFE? IS PATIENT EDUCATION ALWAYS BENEFICIAL?  
Saleem E, Hassali MA, Shafie AA, Aljaidhey H, Haq N, Ali M, 1Universiti Sains Malaysia, Penang, Malaysia, 2King Saud University, Riyadh, Saudi Arabia, 3Alliance University College of Medical Sciences (AUCMS), Penang, Malaysia

**HEALTH CARE EXPENDITURES STUDIES**

**Room 103 (1st Floor)**

**Moderator:** Li Ye, Regional Lead of Payer Capability Asia Pacific, Global Pricing and Market Access, AstraZeneca Singapore Pte. Ltd., Singapore

**6:00PM-6:15PM**

**EX1** THE EFFECTS OF POLYPHARMACY ON HEALTH CARE COSTS AND HOSPITAL ADMISSIONS IN THAI ELDERLY POPULATION: MULTIVARIATE TWO-PART MODELS  
Sruamsiri R, Jeapeeprong N, Jampaichaisri K, Chaiyakunapruk N, 1Center of Pharmaceutical Outcomes Research, Muang, Phitsanulok, Thailand, 2Department of Pharmacy, Muang, Phitsanulok, Thailand, 3Department of Mathematics, Muang, Phitsanulok, Thailand
EX2 AN OBSERVATION ON THE TREND OF OUTPATIENT CLINIC UTILIZATION AND NUMBERS OF MEDICAL PRESCRIPTION GIVEN IN TAIWAN

Hung YN, Yang SY, Wang TC, Chen U, Yu S, National Yang-Ming University, Taipei, Taiwan, "Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan

EX3 AN EVALUATION OF THE EFFECTS FROM CHINA DRUG POLICY REFORM DURING 2009-2011: SOME SUCCESS, MANY UNINTENDED EFFECTS


EX4 RECENT TRENDS IN COMMUNITY PHARMACY PAYMENT OF NATIONAL HEALTH INSURANCE IN SOUTH KOREA

Choi SE, Cheong C, Lee H, Kim J, Lim EA, "Korea University, Yeongi-gun, Chungnam, South Korea, "Seoul National University, Seoul, South Korea

HEALTH TECHNOLOGY ASSESSMENT STUDIES

Room 101 (1st Floor)

Moderator: Miguel Valentin, BA, Director, Global Market Access, Alcon Laboratories, Fort Worth, TX, USA

HT1 WITHDRAWN

HT2 WITHDRAWN

HT3 DEVELOPMENT OF A CHECK LIST FOR QUALITY ASSESSMENT OF PHARMACOECONOMIC EVALUATIONS SUBMITTED FOR REIMBURSEMENT IN TAIWAN

Wu GH, Liao CH, Shau WY, Lo PC, "Center for Drug Evaluation, Taipei, Taiwan, "Taipei Medical University, Taipei, Taiwan

HT4 HEALTH TECHNOLOGY ASSESSMENT MAP IN ASIA – REGIONAL VERSUS INTERNATIONAL INFLUENCES

Andreykiv M, Wiebinga C, Gabel C, Zorzi O, "Quintiles, Hoofddorp, Netherlands, "Quintiles, Singapore

PREFERENCE-BASED OUTCOMES STUDIES

South Lounge (3rd Floor)

Moderator: Alex Z. Fu, PhD, Associate Professor, Georgetown University, Washington, DC, USA

PR1 DOES MEDICATION ADHERENCE CORRELATE WITH HEALTH-RELATED QUALITY OF LIFE? FINDINGS FROM A DESCRIPTIVE ANALYSIS

Saleem E, Hassali MA, Shafie AA, Aljadhey H, Haq N, Asif M, Universiti Sains Malaysia, Penang, Malaysia, "King Saud University, Riyadh, Riyadh, Saudi Arabia, "Al-Mustafa University College of Medical Sciences, Malaysia, Penang, Malaysia

PR2 A FEASIBILITY STUDY OF PREFERENCE-BASED HEALTH-RELATED QUALITY OF LIFE MEASURES ON PATIENTS WITH IRRITABLE BOWEL SYNDROME IN TAIWAN

Hsu CC, Chen LC, Wen YH, Su YC, "Graduate Institute of Clinical Pharmacy, Kaohsiung, Taiwan, "University of Nottingham, Nottingham, Nottingham, UK, "Kaohsiung Medical University, Kaohsiung, Taiwan, "Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan

PR3 UTILITY VALUES FOR CHEMOTHERAPY-RELATED ADVERSE EVENTS: A REVIEW OF THE LITERATURE

Shabbaruddin FH, Chen LC, Elliott R, Payne K, "University of Malaya, Kuala Lumpur, Malaysia, "University of Nottingham, Nottingham, UK, "University of Manchester, Manchester, UK

PR4 THE EFFECT OF NEUROPATHIC PAIN ON HEALTH STATUS, WORK PRODUCTIVITY LOSS, AND HEALTH CARE RESOURCE USE IN JAPAN


7:00PM-8:00PM RESEARCH POSTER AUTHOR DISCUSSION HOUR – SESSION I Room 201 (2nd Floor)

7:00PM-8:30PM RESEARCH POSTER PRESENTATIONS & EXHIBITORS’ RECEPTION Room 201 (2nd Floor)

8:30PM-10:00PM ASIA CONSORTIUM RECEPTION Jade (2nd Floor)

All attendees welcome. Meet leaders from the Asia-Pacific region. Students and newcomers particularly encouraged to attend.

Reception supported by Janssen Asia Pacific, Johnson & Johnson
PROGRAM & SCHEDULE OF EVENTS: TUESDAY, 4 SEPTEMBER

TUESDAY, 4 SEPTEMBER

8:30AM-5:00PM  RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II  Room 201 (2nd Floor)
(See pages 31-54 for Research Poster Presentations)

8:30AM-10:00AM  WELCOME & THIRD PLENARY SESSION  Room 101 (1st Floor)

WELCOME
Surachat Ngorsuraches, PhD, RPh, 2012-2014 ISPOR Asia Consortium Executive Committee Chair, and Associate Professor, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand
(See pages 65-68 for biographical information)

CHALLENGES OF ADOPTING NEW INNOVATIVE TECHNOLOGIES IN HEALTH CARE COVERAGE DECISION-MAKING IN ASIA
(See pages 65-68 for biographical information)
A constant dilemma that payers face is the increasing demands for new health technologies versus their limited resources, and the value of the new technology for targeted therapies, therapeutic devices and diagnostic products, or surgical procedures. Novel strategies have been developed and, to a lesser extent, implemented in some countries, to ease the tension caused by this dilemma. Examples include coverage with evidence development, risk-sharing or performance-based agreement, and others. Speakers in this session will share the recent developments of novel strategies for adopting new technologies, the pros and cons, and the potential for implementation in Asia.
Moderator: Bong-Min Yang, PhD, Professor, School of Public Health, Seoul National University, Seoul, South Korea
Speakers:
Jianying Guo, MA, Director, Department of Price, National Development and Reform Commission (NDRC), Beijing, China
Netnapis Suchonwanich, MA, Assistant Secretary General, National Health Security Office (NHSO), Bangkok, Thailand
Hasbullah Thabrany, MD, PhD, MPH, Professor, Faculty of Public Health, University of Indonesia, Depok, Indonesia
Hong Li, PhD, MPH, Group Director, Global Health Economics and Outcomes Research (GHEOR), Emerging Markets, Japan and Asia, Bristol-Myers Squibb, Wallingford, CT, USA and Adjunct Associate Professor, University of Cincinnati Medical Center, Cincinnati, OH, USA, Duke-National University of Singapore Graduate Medical School, Singapore

Panelists:
Isao Kamae, MD, PhD, Professor of Health Technology Assessment and Public Policy, Graduate School of Public Policy, University of Tokyo, Tokyo, Japan;
Bong-Min Yang, PhD, Professor, School of Public Health, Seoul National University, Seoul, South Korea;
Philippa Delahoy, PhD, Senior Therapeutic Area Manager, Pfizer Australia, Sydney, Australia

10:00AM-10:15AM  BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II  Room 201 (2nd Floor)
(See pages 31-54 for Research Poster Presentations)

10:15AM-11:15AM  ISSUE PANELS & WORKSHOPS – SESSION II  Room 101 (1st Floor)

IP2: PERSONALIZED MEDICINE: HOW CAN WE GO WITH IT?  Room 101 (1st Floor)

Chinese/English Translation

Moderator: Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research & Policy Program, University of Washington School of Pharmacy, Seattle, WA, USA
Panelists: Isao Kamae, MD, DrPH, Professor of Health Technology Assessment and Public Policy, Graduate School of Public Policy, University of Tokyo, Tokyo, Japan; Bong-Min Yang, PhD, Professor, School of Public Health, Seoul National University, Seoul, South Korea; Philippa Delahoy, PhD, Senior Therapeutic Area Manager, Pfizer Australia, Sydney, Australia

IP3: CHALLENGES IN IMPLEMENTING THE 4TH HURDLE IN CHINA  Room 103 (1st Floor)

Chinese/English Translation

Moderator: Seng Chuen Tan, MSC, Director, Double Helix Consulting, Asia-Pacific, Singapore
Panelists: Shanzhan Hu, MD, MSC, Professor of Health Economics & Director, Center for Health Development Research, Shanghai Bureau of Health, School of Public Health, Fudan University, Shanghai, China; Yan Yan Wang, MSC, Assistant Researcher, National Social Security Institute, Ministry of Human Resources and Social Security, Beijing, China; Peng Dong, PhD, Manager, Pharmacoeconomics & Outcomes Research, Pfizer, Beijing, China

IP5: SWITCH EFFECT ANALYSIS FOR RETROSPECTIVE COMPARATIVE EFFECTIVENESS RESEARCH  Room 105 (1st Floor)

Discussion Leaders: Peter Sun, MD, PhD, Vice President, Health Economics & Outcomes Research, Kailo Research Group, Fishers, IN, USA; Boxiong Tang, MD, PhD, Senior Director, Outcomes Research, Pfizer, New York, NY, USA; Hulda Chi Hui Fang, MSC, Associate Outcomes Research Manager, Outcomes Research, Medical Affairs, Pfizer, New Taipei City, Taiwan
ISPOR 5th ASIA-PACIFIC CONFERENCE
2-4 September 2012 ▪ Taipei, Taiwan

PROGRAM & SCHEDULE OF EVENTS: TUESDAY, 4 SEPTEMBER continued

W6: EVALUATING EVIDENCE FOR MEDICAL DEVICES – INTERNATIONAL EXPERIENCES  North Lounge (3rd Floor)
Discussion Leaders: George Wells, MSc, PhD, Professor, Epidemiology and Community Medicine and Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada; Jeonghoon Ahn, PhD, MA, Senior Director, Office of Health Services Research, National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea; Yen-Fu Chen, MSc, MPH, PhD, Research Fellow, Department of Public Health, Epidemiology and Biostatistics, University of Birmingham, Edgbaston, Birmingham, UK; Jasmine Raoh-Fang Pwu, PhD, Director, Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan

W7: REALITIES OF POPULATING GLOBAL MODELS IN ASIA  South Lounge (3rd Floor)
Discussion Leaders: Kenneth K.C. Lee, MPhil, PhD, Professor of Pharmacy, Pharmacy/School of Medicine and Health Sciences, Monash University Sunway Campus, Selangor, Malaysia; Soraya Azmi, MBBS, MPH, Managing Director, Azmi Burhani Consulting, Petaling Jaya, Selangor, Malaysia; Kathleen Yeoh, BSc, (Hons), Government Affairs & Market Access Manager, Bayer Healthcare Pharmaceuticals, Bayer Co. (Malaysia) Sdn. Bhd., Petaling Jaya, Selangor, Malaysia; Lachlan Standfield, Biotech, (Hons), Associate Director, Health Economics and Outcomes Research, OptumInsight, Sydney, NSW, Australia

11:15AM-12:15PM  RESEARCH POSTER AUTHOR DISCUSSION HOUR – SESSION II  Room 201 (2nd Floor)
(See pages 31-54 for Research Poster Presentations)

11:45AM-2:45PM  LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II  Room 201 (2nd Floor)
(See pages 31-54 for Research Poster Presentations)

12:15PM-1:15PM  EDUCATIONAL SYMPOSIUM  Room 101 (1st Floor)
(See page 64 for Symposium description)
TARGETED THERAPIES – ARE WE READY? CHALLENGES AND PITFALLS FOR SPONSORS AND DECISION-MAKERS ALIKE
Sponsored by OptumInsight

1:30PM-2:30PM  EDUCATIONAL SYMPOSIUM  Room 101 (1st Floor)
(See page 64 for Symposium description)
UNDERSTANDING ASIA’S PAYER’S PERSPECTIVE ON ACUTE CORONARY SYNDROME
Sponsored by AstraZeneca

2:45PM-3:45PM  ISSUE PANELS & WORKSHOPS – SESSION III

IP4: USING MAPPED EQ-5D FROM DISEASE-SPECIFIC MEASURES IN COST-UTILITY ANALYSIS: WHAT IS THE CURRENT STATE IN ASIA PACIFIC?  Room 105 (1st Floor)
Moderator: Ittratuk Leartsakulpanitich, PhD, Director, Market Access, Asia Pacific, Johnson & Johnson Asia Pacific, Bangkok, Thailand
Panelists: Eui Kyung Lee, PhD, Professor; Pharmaceutical Policy & Outcomes Research, School of Pharmacy, Sungkyunkwan University, Seoul, South Korea; Chin-Fang Chou, PhD, Director, Patient-Reported Outcomes, Janssen Global Services, Companies of Johnson & Johnson, West Hills, CA, USA; Bruce Crawford, MA, MPH, Managing Director, Asia and Senior Vice President, Adelphi Values, Tokyo, Japan

W8: ONE SIZE FITS ALL? ADAPTING GLOBAL MODELS FOR LOCAL NEEDS  Room 103 (1st Floor)
Discussion Leaders: Chao-Hsien Tang, PhD, Professor, Health Care Administration, Taipei Medical University, Taipei, Taiwan; Andrew H. Briggs, DPhil, MSc, William R. Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK; Tracy A. Comans, PhD, Research Fellow, Centre for Applied Health Economics, Griffith University, Meadowbrook, Queensland, Australia; Jasmine Raoh-Fang Pwu, PhD, Director, Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan

W9: EQUITY IN PRICING AND REIMBURSEMENT DECISIONS ACROSS ASIA PACIFIC COUNTRIES  Room 101 (1st Floor)
Chinese/English Translation
Discussion Leaders: Rutger Daems, PhD, Planet Strategy Group, Brussels, Belgium; Surachat Ngorsuraches, PhD, Assistant Professor, Faculty of Pharmaceutical Science, Hatyai, Thailand; Christoph Gaetzer, DiplKfm, Vice President, Market Access, Asia-Pacific, Johnson & Johnson, Singapore, Singapore; Steven Crowley, MSc, Executive Director, Integrated Market Access, Janssen Cilag Australia, NSW, Australia

W10: FACTORS ASSOCIATED WITH PHARMACEUTICAL REIMBURSEMENT OUTCOME IN AUSTRALIA: REVIEW OF APPRAISALS OF MANUFACTURERS’ SUBMISSIONS SINCE 2005  North Lounge (3rd Floor)
Discussion Leaders: Dominic Tilden, MPh, Managing Director, TEMA Consulting Pty. Ltd., Pyrmont, NSW, Australia; Michael Aristides, MSc, Managing Director, Value-Med Consulting Pty. Ltd., Waverley, NSW, Australia; George Papadopoulos, BSc(Hons), Managing Director, Emerald Corporate Group P/L, Mosman, NSW, Australia

W11: TRICKS AND TRAPS IN ASSESSING PATIENT COMPLIANCE USING PRESCRIPTION CLAIMS DATABASES  South Lounge (3rd Floor)
Discussion Leaders: Michael Ortiz, PhD, Associate Professor, University of NSW, Darlinghurst, NSW, Australia; Gordon Calcino, GradDipMedSta, Director, HI Connections Pty. Ltd., Woden, ACT, Australia; Lisa Calcino, BA, Director, HI Connections Pty. Ltd., Woden, ACT, Australia
ISPOR 5th ASIA-PACIFIC CONFERENCE
2-4 September 2012 ■ Taipei, Taiwan

PROGRAM & SCHEDULE OF EVENTS: TUESDAY, 4 SEPTEMBER continued

3:45PM-4:00PM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II
Room 201 (2nd Floor)
(See pages 31-54 for Research Poster Presentations)

4:00PM-5:00PM ISSUE PANELS & WORKSHOPS – SESSION IV

IPS: DOES PRICE DISCRIMINATION HAVE A PLACE IN PHARMACEUTICAL PRICING IN ASIA? Room 101 (1st Floor)

Chinese/English Translation
Moderator: Adèle R. Weston, PhD, Vice President & Senior Scientist, OptumInsight, Lilyfield, NSW, Australia
Panelists: Gilberto de Lima Lopes, MD, MBA, FAMS, Program Leader for Health Economics and Policy, School of Medicine, Johns Hopkins University, Singapore; Mendel Grobler, MBA, Director, Access and Patient Affairs, Pfizer Australia, West Ryde, NSW, Australia; Michael Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

W12: DECISION MAKING IN HEALTH TECHNOLOGY ASSESSMENT Room 103 (1st Floor)
Discussion Leaders: Olivia Wu, PhD, Reader in Health Economics, Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK; Neil Hawkins, PhD, Vice President, Health Economics, Oxford Outcomes, Oxford, UK; Jasmine Raoh-Fang Pwu, PhD, Director, Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan

W13: GOVERNMENT AND INDUSTRY PARTNERSHIPS FOR KOREAN PHARMACEUTICAL POLICY: GOOD PRACTICE REVIEW Room 105 (1st Floor)
Discussion Leaders: Bong-Min Yang, PhD, Professor, School of Public Health, Seoul National University, Seoul, South Korea; Mi-Young You, MPH, General Manager, Drug Listing Division, Health Insurance Review & Assessment Service, Seoul, South Korea; Chang-Ik Kwon, PhD, Manager of HEHTA, External Affairs, Handok Pharmaceuticals, Seoul, South Korea; Eui Kyung Lee, PhD, Professor of Pharmaceutical Policy & Outcomes Research, School of Pharmacy, Sungkyunkwan University, Seoul, South Korea

W14: CHALLENGES AND LESSONS FOR ESTABLISHING PRICING REGULATIONS IN ASIAN PACIFIC COUNTRIES North Lounge (3rd Floor)
Discussion Leaders: Konrad Wallerstein, MA, Managing Director, Wallerstein Access LLC, Belle Mead, NJ, USA; George Papadopoulos, BSc(Hons), Managing Director, Emerald Corporate Group P/L, Mosman, NSW, Australia

W15: CONDUCTING REAL-WORLD STUDIES IN EMERGING ASIAN MARKETS South Lounge (3rd Floor)
Discussion Leaders: Nuria Lara, MD, MSc, Medical Director Observational Center of Excellence, Health Economics & Outcomes Research, IMS Health, Barcelona, Spain; Joe Caputo, Principal, APAC, Health Economics & Outcomes Research, IMS Health, Singapore, Singapore; Hung-Jen Lai, MD, Medical Director, Merck, Sharp & Dohme Corp., Taipei, Taiwan; Grace Yi-Yin Huang, Consultant, CE and PMR, IMS Health, Taipei, Taiwan

5:15PM-6:00PM ISPOR SERVICE & RESEARCH AWARDS PRESENTATION, ISPOR 6th ASIA-PACIFIC CONFERENCE ANNOUNCEMENT & CLOSING REMARKS Room 101 (1st Floor)

Chinese/English Translation
Moderated by: Surachat Ngorsuraches, PhD, RPh, 2012-2014 ISPOR Asia Consortium Executive Committee Chair, and Associate Professor, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand

ISPOR DISTINGUISHED SERVICE AWARDS PRESENTATION
Presented by: Deborah Marshall, PhD, MHSA, 2012-2013 ISPOR President, Research Chair, Health Services and Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary and Director, Health Technology Assessment, Alberta Bone and Joint Health Institute, Calgary, AB, Canada

AWARDEES:
Yen-Huei (Tony) Tarn, MS, PhD, ISPOR 5th Asia-Pacific Conference Program Committee Co-Chair and Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan
Chee-Jen Chang, PhD, ISPOR 5th Asia-Pacific Conference Program Committee Co-Chair, Director, Clinical Informatics and Medical Statistics Research Center and Professor, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan
Bong-Min Yang, PhD, 2010-2012 ISPOR Asia Consortium Executive Committee Chair and Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea
Hong Li, PhD, MPH, 2005-2007 ISPOR Asia Consortium Advisory Committee, Chair and Group Director, Global Health Economics and Outcomes Research (GHEOR), Emerging Markets, Japan and Asia, Bristol-Myers Squibb Company, Wallingford, CT, USA
Jeff J. Guo, PhD, 2007-2009 ISPOR Asia Consortium Advisory Committee Chair, and Professor of Pharmacoconomics & Pharmacoeconomics, College of Pharmacy, University of Cincinnati Medical Center, Cincinnati, OH, USA

ISPOR RESEARCH AWARDS PRESENTATION
Presented by: Hui-Chu Lang, BSc, PhD, President, ISPOR Taiwan Chapter (TaSPOR), and Professor, Institute of Hospital and Health Care Administration, National Yang Ming University Taipei, Taiwan
Chee-Jen Chang, PhD, Director, Clinical Informatics and Medical Statistics Research Center, Professor, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan
ISPOR 5th ASIA-PACIFIC CONFERENCE

PROGRAM & SCHEDULE OF EVENTS: TUESDAY, 4 SEPTEMBER continued

ISPOR 6TH ASIA-PACIFIC CONFERENCE ANNOUNCEMENT
Shanlian Hu, MD, MSc, Professor of Health Economics, School of Public Health, Fudan University, Shanghai, Mainland China

CLOSING REMARKS
Yen-Huei (Tony) Tarn, MS, PhD, Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan
Chee-Jen Chang, PhD, Director, Clinical Informatics and Medical Statistics Research Center, Professor, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan

Value in Health Regional Issues
Asia 2013 Issue

Call for Papers!

Criteria of a Manuscript to be considered:
1. One of the Authors of an article should reside in Asia, and
2. Empirical study articles should include subjects from population(s) in Asia

To submit a manuscript, please go to http://www.ispor.org/publications/VIHRI/VIHRImain.asp.

Manuscript submission deadline: September 15, 2012

News Across Asia
September-December, 2012 (Autumn Issue)

Call for News!

News Across Asia, an electronic newsletter of the ISPOR Asia Consortium, is a communication channel for sharing information, ideas and the trends of health care policies, outcomes research and pharmaco economics education in Asia.

To submit news, please email it to: asiaconsortium@ispor.org
ISPOR Regional Consortia and Chapters encourage the geographical development of pharmaceconomics and the global flow of ideas and information related to health care decision-making. Membership is open to all, based on geographical location. The following is a listing of the ISPOR meetings being held during the ISPOR 5th Asia-Pacific Conference.

*Please note that these meetings are by prior invitation only. However, ISPOR encourages your future involvement in ISPOR's Consortia and Chapters.*

### ASIA CONSORTIUM MEETINGS

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Meeting</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, 2 Sep</td>
<td>7:00pm-9:00pm</td>
<td>ISPOR 5th Asia-Pacific Conference Program Committee Co-Chairs Meeting</td>
<td>402 (4th Floor)</td>
</tr>
<tr>
<td>Monday, 3 Sep</td>
<td>7:15am-8:15am</td>
<td>ISPOR Asia Consortium Industry Committee Meeting</td>
<td>203A (2nd Floor)</td>
</tr>
<tr>
<td></td>
<td>12:00pm-1:15pm</td>
<td>ISPOR Asia Consortium Publication Committee Meeting</td>
<td>203A (2nd Floor)</td>
</tr>
<tr>
<td></td>
<td>1:45pm-2:45pm</td>
<td>ISPOR Asia Consortium Education Committee Meeting</td>
<td>203A (2nd Floor)</td>
</tr>
<tr>
<td>Tuesday, 4 Sep</td>
<td>7:15am-8:15am</td>
<td>ISPOR Asia Consortium Clinicians, HTA Agencies, Policymakers &amp; Payers Committee Meeting</td>
<td>203A (2nd Floor)</td>
</tr>
<tr>
<td></td>
<td>11:45am-1:00pm</td>
<td>Value in Health Regional Issues Editorial Board &amp; Editorial Advisory Board (Asia) Meeting</td>
<td>203A (2nd Floor)</td>
</tr>
<tr>
<td></td>
<td>1:30pm-2:30pm</td>
<td>ISPOR Asia Consortium Executive Committee Meeting</td>
<td>203A (2nd Floor)</td>
</tr>
<tr>
<td></td>
<td>6:00pm-7:00pm</td>
<td>ISPOR Asia Consortium Advisory Committee Meeting</td>
<td>203A (2nd Floor)</td>
</tr>
<tr>
<td>Wednesday, 5 Sep</td>
<td>8:30am-4:00pm</td>
<td>HTAnet Asia Round Table</td>
<td>Grand Hyatt, Residence Two</td>
</tr>
</tbody>
</table>

Asia Consortium membership is open to all in and outside of Asia, who are interested in advancing the science of Pharmacoeconomics (health economics) and outcomes research and its use in healthcare decisions in Asia.

For information: [www.ispor.org](http://www.ispor.org) >> Regional Consortia >> Asia Consortium

### REGIONAL CHAPTER MEETINGS

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Meeting</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, 3 Sep</td>
<td>7:15am-8:15am</td>
<td>ISPOR Beijing, Chinese MDA-PE, Hong Kong &amp; Shanghai Chapters Meeting</td>
<td>202A (2nd Floor)</td>
</tr>
<tr>
<td></td>
<td>12:00pm-1:15pm</td>
<td>ISPOR Japan &amp; Taiwan Chapters Meeting</td>
<td>202A (2nd Floor)</td>
</tr>
<tr>
<td></td>
<td>1:45pm-2:45pm</td>
<td>ISPOR Kazakhstan &amp; Mongolia Chapters Meeting</td>
<td>202A (2nd Floor)</td>
</tr>
<tr>
<td></td>
<td>4:45pm-5:45pm</td>
<td>ISPOR Thailand Chapter Meeting</td>
<td>202A (2nd Floor)</td>
</tr>
<tr>
<td>Tuesday, 4 Sep</td>
<td>7:15am-8:15am</td>
<td>ISPOR India, India-Andhra Pradesh &amp; India-Karnataka Chapters Meeting</td>
<td>202A (2nd Floor)</td>
</tr>
<tr>
<td></td>
<td>11:45am-1:00pm</td>
<td>ISPOR Indonesia, Malaysia, Singapore Chapters Meeting</td>
<td>202A (2nd Floor)</td>
</tr>
<tr>
<td></td>
<td>1:30pm-2:30pm</td>
<td>ISPOR Korea Chapter Meeting</td>
<td>202A (2nd Floor)</td>
</tr>
</tbody>
</table>

Regional Chapter membership is open to all who reside in the country/area the Chapter represents.

For information: [www.ispor.org](http://www.ispor.org) >> Regional Chapters & Networks >> ISPOR Regional Chapters

Please note: Invitees will receive an e-mail reminder & notification of any changes to these scheduled meetings.
ISPOR 5th ASIA-PACIFIC CONFERENCE
2-4 September 2012 Taipei, Taiwan

CONFERENCE ROOM FLOOR PLANS

1st floor

2nd floor

3rd floor

4th floor

Legend

- Emergency Exit
- Rest Room
- Telephone
- Lift